Our group studies the molecular mechanisms underlying Gram-negative bacterial infections to develop antibacterial drugs that are not susceptible to existing resistance mechanisms.
Our group works on protection of humans and crops from pathogens. We do this by studying natural defences of plants, and the biology of the pathogens themselves.
Our research aims to understand the link between what immune cells ‘eat’ in our tissues and how this is connected to their normal biology and inflammatory diseases such as high blood pressure and diabetes.
Our group specialises in CD8+ T cell biology and antigen processing and presentation, particularly in relation to the development of cross-protective immune responses to the influenza virus.
Our group studies AAA+ proteases, responsible for general and regulated protein turn over in bacteria and in some organelles of eukaryotes.
Our group uses single domain antibodies that have been developed from sharks to identify novel therapeutics against a number of chronic diseases.
Our laboratory is focused on understanding how to combat viral infections.
Our group uses a combination of biochemistry, molecular and cell biology to investigate neurodegenerative diseases such as Alzheimer's, Prion and Parkinson's diseases.
Our group studies the molecular basis of tumour progression and inflammatory disease to develop novel anti-cancer and anti-inflammatory drugs.
Our group studies the molecular interactions in signal transduction networks regulating inflammation.
Our group uses zebrafish models to discover and understand molecular pathways in blood cell development and disease.
Our group examines the neurobiology and neurochemistry that underlies the physiology of metabolism.
Our group examines how viruses hijack cellular defence systems to ensure their own proliferation and survival.
Our group uses proof-of-concept to identify pathological and molecular mechanisms of disease. We also evaluate candidate MS drugs.
Our research group applies genomics for tracking the origin and spread of infectious diseases.
Our group studies the machinery that control how dying cells can disassemble into smaller pieces, and the importance of cell disassembly in disease settings, to identify new drugs to control this process.
Our group researches the molecular basis of apoptosis regulation during heart failure, sepsis and in chemo resistance.
Our group studies the use of bacteriophage as alternatives to antibiotics. We also examine the personalization of medicine to fit a patient's genetic profile, and patient management of medication in the treatment of chronic disease.
Our group studies animal models to discover novel mechanisms underlying reproductive, developmental, and immune functions.
Our group researches enzymes, called proteases, which operate at the interface between a host, such as a human being and microbes that cause disease.